Myeloma Video Channel
Explore the latest insights and summaries from experts in Myeloma.
Therapeutic Agents
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Insights: "DREAMM-7 Trial - BelamafVd vs. DaraVd in R/R MM"
FEATURING
Maria-Victoria Mateos
- 288 views
- June 6, 2024
- 1
MyCancerHaven
Isatuximab in 1L Transplant-Ineligible Myeloma
FEATURING
Ravi Vij,
Adriana Rossi
- 29 views
- August 30, 2024
SOHO Brazil 2024
Managing Infectious Complications With Bispecific and CAR-T Therapy in MM
FEATURING
Noopur S. Raje
- 193 views
- July 11, 2024
- 2
MyCancerHaven
Will CAR-Ts and Bispecifics Replace HSCT in Myeloma?
FEATURING
Ravi Vij,
Samer Al Hadidi
- 622 views
- May 23, 2024
- 5
Insights from 2024 EHA Annual Meeting
Highlights in Plasma Cell Disorders From ASCO® and EHA
FEATURING
Samer Al Hadidi
- 471 views
- June 27, 2024
- 7
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Summary: "Comparative Review of Toxicities and Their Management With Bispecific Agents in MM and B-Cell NHL"
FEATURING
Monique Minnema
- 283 views
- June 7, 2024
- 4
Dana-Farber Cancer Institute
CAR T-Cells in Multiple Myeloma in 2024
FEATURING
Adam Sperling
- 268 views
- July 2, 2024
- 4
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Insights: "Indirect Comparison of Linvoseltamab Vs. Teclistamab for Triple-Class Exposed R/R MM"
FEATURING
Sundar Jagannath
- 184 views
- June 17, 2024
- 2
Stanford Medicine
Risk of Second Malignancies and T-Cell Lymphoma After CAR T-Cell Therapy
FEATURING
Mark Hamilton
- 194 views
- June 28, 2024
- 3
ecancer
ASCO® 2024 Summary: "IMROZ & BENEFIT Studies in Newly Diagnosed Myeloma"
FEATURING
Xavier Leleu
- 182 views
- June 24, 2024
- 1
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Insights: "The BENEFIT Study - Isa-VRd vs. Isa-Rd for Transplant-Ineligible NDMM"
FEATURING
Xavier Leleu
- 155 views
- June 11, 2024
UCSF School of Medicine
Best of ASCO® 2024: Myeloma Highlights and Practice Impacts
FEATURING
Ajai Chari
- 171 views
- August 7, 2024
- 2
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Summary: "Current Status of Bispecific Antibody Therapy in R/R MM"
FEATURING
Meera Mohan
- 158 views
- June 16, 2024
- 1
Rush University Medical Center
BCMA & Beyond: Novel Targets for Immunotherapy in MM
FEATURING
Ben Derman
- 158 views
- June 14, 2024
- 2
Supratik Basu
How I Approach Switching to Daratumumab SC From IV in Patients With MM
- 118 views
- August 2, 2024
- 2
Dana-Farber Cancer Institute
Future of Novel Next Generation Therapy in the Management of R/R MM
FEATURING
Paul Richardson
- 218 views
- June 18, 2024
- 3
ecancer
ASCO® 2024 Insights: "CARTITUDE-4 Study - Benefits of Ciltacabtagene Autoleucel in Lenalidomide-Refractory Functional High-Risk MM"
FEATURING
Luciano Costa
- 109 views
- June 24, 2024
ecancer
ASCO® 2024 Insights: "IMROZ - A Ph3 Study of Isatuximab + VRd vs. VRd for Transplant-Ineligible NDMM"
FEATURING
Thierry Facon
- 109 views
- June 24, 2024
Insights from 2024 EHA Annual Meeting
EHA 2024 Insights: PERSEUS Trial MRD Analysis: Dara + VRd in Transplant-Eligible NDMM
FEATURING
Pieter Sonneveld
- 95 views
- June 20, 2024
ecancer
ASCO® 2024 Insights: "Results of Preliminary Safety & Efficacy of Belantamab Mafodotin and Elotuzumab in R/R MM"
FEATURING
Natalia Neparidze
- 73 views
- June 25, 2024
ecancer
ASCO® 2024 Insights: "MajesTEC-7 Study - Safety and Efficacy of Tec-DR in NDMM"
FEATURING
Salomon Manier
- 67 views
- June 26, 2024
ecancer
ASCO® 2024 Insights: "Importance of MRD in Newly Diagnosed Multiple Myeloma"
FEATURING
Xavier Leleu
- 78 views
- July 18, 2024
- 1
Nebraska Oncology Society
Therapeutic Potential of Bispecific Antibodies and BiTEs in Treating MM
FEATURING
Al-Ola Abdallah
- 61 views
- July 10, 2024
Insights from 2024 EHA Annual Meeting
EHA 2024 Insights: Results by Cytogenetic Risk From PERSEUS - Dara-VRd in Transplant-Eligible Newly Diagnosed MM
FEATURING
Meletios Dimopoulos
- 71 views
- July 5, 2024
- 1
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Insights: "New Agents on the Horizon in NHL and Myeloma - Targets Other Than CD3/CD20, New Constructs, and Trispecifics"
FEATURING
Paolo Strati
- 47 views
- June 12, 2024
MyCancerHaven
Experts Discuss How They Plan to Use CAR-T in Myeloma After First Relapse
FEATURING
Ravi Vij,
Al-Ola Abdallah
- 71 views
- August 30, 2024
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Current Overview of Biscpecific Antibodies in Hematologic Malignancies
FEATURING
Bahar Uncu Ulu
- 50 views
- August 15, 2024
Dana-Farber Cancer Institute
Bispecific Antibody Therapy in Multiple Myeloma
FEATURING
Shonali Midha
- 58 views
- July 1, 2024
MyCancerHaven
DreaMM-7 and DreaMM-8: Ready for the Return of Belamaf in Myeloma?
FEATURING
Ravi Vij,
Ajai Chari
- 98 views
- September 3, 2024
ecancer
EHA 2024 Insights: DREAMM-8 Trial Summary - Belamaf + PomDex Vs. Bortezomib + PomDex in R/R MM
FEATURING
Meletios Dimopoulos
- 32 views
- July 24, 2024
Insights from 2024 EHA Annual Meeting
EHA 2024 Insights: Infectious Complications in BCMA- and GPRC5D-Targeted Immunotherapy for MM
FEATURING
Julia Mersi
- 28 views
- July 2, 2024
ecancer
ASCO® 2024 Insights: "Long-Term Follow-Up of MajesTEC-1 Trial - Teclistamab in R/R MM"
FEATURING
Alfred Garfall
- 27 views
- June 20, 2024
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Current Status of Lenalidomide Maintenance in Myeloma
FEATURING
Ant Uzay
- 16 views
- August 15, 2024
MyCancerHaven
Isatuximab in 1L Transplant-Ineligible Myeloma
FEATURING
Ravi Vij,
Adriana Rossi
- 29 views
- August 30, 2024
Samer Al Hadidi
CAR-Ts Earlier in MyelomaTherapy?: What We Learned From the Recent FDA ODAC Meeting
- 600 views
- March 29, 2024
- 3
Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient
Managing Newly Diagnosed Myeloma in 2024
FEATURING
Alfred Garfall
- 428 views
- March 11, 2024
- 1
Moffitt Cancer Center
State-of-the-Art: Bispecific Antibodies in Myeloma - Which? How? When?
FEATURING
Ariel Grajales-Cruz
- 267 views
- March 4, 2024
- 6
MyCancerHaven
Multiple Myeloma: Experts Discuss How to Choose Between CAR-Ts and Bispecifics
FEATURING
Ravi Vij,
Nitya Nathwani
- 260 views
- May 2, 2024
- 2
Indy Hematology Review
Multiple Myeloma: Understanding Your Immune Effector Therapeutic Options
FEATURING
Saad Usmani
- 230 views
- April 18, 2024
- 2
Indy Hematology Review
2024 Updates on Understanding & Managing Immune Effector Cell Toxicities in Hematologic Malignancies
FEATURING
David Reeves
- 239 views
- April 30, 2024
- 2
Moffitt Cancer Center
CAR T-Cell Therapies for Pts With R/R Myeloma: Updates From the Real World
FEATURING
Doris Hansen
- 244 views
- May 24, 2024
- 1
Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient
2024 Updates in MM: The Role of Immunotherapy
FEATURING
Adam D. Cohen
- 285 views
- March 1, 2024
- 4
ecancer
PERSEUS Trial Summary: Adding Daratumumab to VRd as a Frontline Therapy for Newly Diagnosed MM
FEATURING
Pieter Sonneveld
- 193 views
- March 5, 2024
- 2
Insights from 2023 ASH Annual Meeting
RRMM: Effects of Ide-Cel vs. Standard Regimens on HRQoL in Patients Who Had Received 2-4 Prior Regimens - Updated Results From KarMMa-3
FEATURING
Michel Delforge
- 174 views
- January 8, 2024
Louisville Hematology Highlights
New Directions in CAR-T: Targeting Novel Antigens
FEATURING
Robert Emmons
- 146 views
- February 27, 2024
- 2
Saurabh Chhabra
BCMA-Directed Bispecifics in MM: Clinical Data & Guidelines for AE Management
- 147 views
- May 21, 2024
- 1
GRACE
Updates on Bispecific Antibodies in Myeloma
FEATURING
Sridevi Rajeeve
- 144 views
- February 15, 2024
- 2
Lucio Gordan
Impact of a Best Practices Program in Patients With R/R MM Receiving Selinexor
- 128 views
- April 8, 2024
- 1
GRACE
Overview on Current Immunotherapy Options in Myeloma
FEATURING
Sridevi Rajeeve
- 121 views
- February 15, 2024
- 1
Yale Cancer Center
Advances in CAR-Ts in Myeloma: Recent Research & Clinical Findings
FEATURING
Noffar Bar
- 106 views
- May 20, 2024
Insights from 2023 ASH Annual Meeting
High-Risk NDMM: KarMMa-2 Extended Follow-Up - Ide-Cel in HR-NDMM Patients With Inadequate Response to Frontline AutoSCT
FEATURING
Melissa Alsina
- 121 views
- January 24, 2024
Oncology Data Advisor
Lowering Talquetamab Dose Intensity to Improve Tolerability in MM - Results From MonumenTAL-1
FEATURING
Ajai Chari
- 94 views
- February 12, 2024
MyCancerHaven
Experts Discuss CELMoDs in MM: Current Data and Future Applications
- 89 views
- May 23, 2024
- 1
MyCancerHaven
Incorporating Selinexor Into the Myeloma Practice
FEATURING
Ravi Vij,
Cristina Gasparetto
- 84 views
- May 22, 2024
Icahn School of Medicine at Mount Sinai
AACR 2024 Insights: "Linvoseltamab, a BCMA-Targeted BsAb, in Pts With R/R Myeloma Including Difficult-to-Treat Subgroups"
FEATURING
Sundar Jagannath
- 64 views
- May 2, 2024
MyCancerHaven
How I Manage Myeloma Patients Long Term After Bispecific or CAR-T Therapy
FEATURING
Ravi Vij,
Binod Dhakal
- 66 views
- February 22, 2024
- 1
UChicago Medicine
CAR-Ts in Heme Malignancies: Practical Perspectives on Trials, Access, and Future Directions
- 33 views
- March 29, 2024
GRACE
The Future of Bispecific Antibodies in Myeloma
FEATURING
Sridevi Rajeeve
- 28 views
- March 6, 2024
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
IKEMA Trial Final Updates: Carfilzomib/Dex +/- Isatuximab in Patients With R/R MM
FEATURING
Ecenur Güder Arslan
- 26 views
- February 15, 2024
XIV Eurasian Hematology-Oncology Congress - EHOC 2023
How I Manage Infections in Myeloma to Decrease Morbidity/Mortality
FEATURING
Ajai Chari
- 32 views
- February 16, 2024
COR2ED The Heart of Medical Education
Optimizing the Management of Multiple Myeloma in the Early R/R Setting
- 101 views
- July 11, 2024
XV Eurasian Hematology-Oncology Congress - EHOC 2024
Overview of R/R Multiple Myeloma and Data on Carfilzomib
FEATURING
Tulin Tuglular
- 15 views
- September 11, 2024